Table 1.
Summary of Vaccine Trials in Metastatic or Advanced RCC
| Vaccine | Trial | No. Evaluable | Efficacy, no. (%) |
|---|---|---|---|
| Dendritic cell/tumor | Holtl et al 19999 | 7 | PR: 1 (14) |
| lysate vaccines | Rieser et al 200010 | ||
| Kugler et al 200011 | 17 | CR: 4 (24) | |
| PR: 2 (12) | |||
| Chang et al 200212 | 33 | CR: 4 (12) | |
| PR: 4 (12) | |||
| Gurjal et al 200113 | 16 | OR: 1 (6) | |
| Dillman et al 200116 | 26 | Patients without evidence of disease | |
| at time of treatment, OR: 5 (19) | |||
| Patients with measurable disease at | |||
| time of treatment, OR: 0 | |||
| Heat shock protein vaccines | Amato et al 199924 | 29 | CR: 1 (3) |
| PR: 3 (10) | |||
| Amato et al 200025 | 25 | CR: 1 (4) | |
| PR: 1 (4) |
RCC, renal cell carcinoma; PR, partial response; CR, complete response; OR, overall response